

Strategic priorities for the OECI

Quality improvement in Cancer Care and Research

The Accreditation and Designation Programme, specifically designed for cancer centres, aims to constantly improve our cancer centres' organisation. Although physicians, nurses and researchers constitute the core of cancer care and research, a seamless organisation, efficient logistics and state of the art, complex infrastructure are needed in order to deliver high quality care to a maximum of cancer patients, throughout Europe, and with a multidisciplinary approach. About 50% of the OECI Members are already included in the A&D Programme. The OECI quality approach is now recognised as the only existing European process specifically designed for cancer centres, providing a significant impact in the quality of cancer care in Europe. The certified Institutes represent the so-called "OECI Quality Network".

In addition to the A&D Programme, OECI established a detailed and focused benchmarking of comprehensive cancer care to transfer best practices amongst OECI members, as well as disseminating them across the entire cancer community.

Enhancing the partnership patients-cancer institutes

Although in-depth integration of cancer research into care and education are the tripod of OECI objectives, the Organisation is moving towards enhancing the partnership with patient associations, involving cancer patients into our thinking and actions. This interest is confirmed by the strategic alliance with the European Cancer Patient Coalition - ECPC, with whom the OECI agreed on specific initiatives to empower the involvement of patients. Bringing together patient organisations and cancer institutes will provide a coherent picture of today's cancer patients' expectations, ranging from: quality of care to information on survivorship and medical nutrition, improvement in the quality of interdisciplinary patient treatment, harmonisation in oncology healthcare practices and patient advocacy capacity to effectively tackle cancer care inequalities in Europe. The foundation of this initiative is a jointly agreed Declaration between Patients and Health Care Providers.

Biobanks and Molecular Pathobiology

Handling tumour heterogeneity and molecular signatures are the basis of the stratification of cancer patients, and clinical research is increasingly integrated with practical medical applications. In view of the crucial role of pathology departments, and of the expected "influx" of new markers and diagnostics in a scope of "OMICS", the OECI WG on Biobanks and Molecular Pathobiology acts in close cooperation with the European Association for Cancer Research EACR, the BBMRI European infrastructure, the European Society of Pathology and the IMPACTS network.

The aims of the WG is to avoid irreproducibility of clinical research, to accelerate the waiting time for biomarkers validation, to give to cancer centres of excellence more opportunities to define personalised treatments, and to improve the use of clinical tissues.

The OECI collaborates with the European biobanks Infrastructures (BBMRI-ERIC) for Archive tissues, with the European Society of Pathology (ESP) for the standardisation of analysis methods, with CEN to improve pre-analytical conditions of tissues, with EACR by organising courses and meetings.

Cancer Outcomes Research

A new working group on cancer outcomes research has been activated in response to the need of following-up prospectively cohorts of patients. For CCCs located in areas covered by population registries, comparative analyses between population and clinical sets of patients will be possible, using EURO CARE and High Resolution data on survival and outcomes.

OECI and rare cancers

OECI is particularly involved in the care of patients suffering from rare cancers. An even higher discrepancy in patient outcomes, depending where they are treated, is still observed. OECI coordinates the work package on quality of care of the Joint Action on Rare Cancers, recently launched by the Directorate General for Health and Consumer Protection of the European Commission. OECI also acts as associate partner and facilitator of the European Reference Network on rare solid tumours in adults; an impressive network of cancer centres of reference for rare cancers that is partially based on OECI quality standards. The network, coordinated by the Centre Léon Bérard in Lyon, involves several cancer centres from 18 countries, with a large percentage coming from OECI membership.

Supportive and Palliative care

The Supportive and Palliative Care Working Group aims to improve the quality of life of cancer patients and their families helping them to cope with the illness and live as actively as possible by the prevention and treatment of physical, psychosocial and spiritual suffering. The WG intends to share a common vision of modern early integrated palliative and supportive care, to develop appropriate quality indicators and standards for care service in the OECI member institutes and to implement clinical and health service research projects through the OECI network of palliative care units in collaboration with other European networks of palliative care.

Education and Training

Educational activities focus, more particularly, on the above mentioned fields and are flourishing in order to strengthen the OECI objectives and to disseminate the acquired knowledge. A special educational programme is jointly developed with the European Association for Cancer Research "EACR". The OECI is also involved in broadcasting the educational programme of the European School of Oncology "ESO", a full OECI member. A specific e-learning programme is under development with the e-cancermedicalscience journal.

Communication and Dissemination

Regular updates of the Organisation are published on the website oeci@oeci.eu.

e-cancermedicalscience (the official OECI e-journal), hosts cutting edge papers, news, reports and videos. Formal collaborations have been established with the following reviews: Cancerworld www.cancerworld.org, and Tumori Journal www.tumorijournal.com.

Both the printed versions are distributed free of charge to the OECI Members and host announcements of OECI events and initiatives.

OECI
BOARD
2017



President
Dominique de Valeriola
Brussels, Belgium



Former President
Wim H. van Harten
Amsterdam, The Netherlands



Treasurer
José Maria Laranja Pontes
Porto, Portugal



Elected Member
Carlos Caldas
Cambridge, United Kingdom



Elected Member
József Lövey
Budapest, Hungary



OECI Director
Claudio Lombardo
Brussels, Belgium - Genoa, Italy



President Elect
Thierry Philip
Paris, France



Executive Secretary
Marco A. Pierotti
Milan, Italy



Elected Member
Gunnar Sæter
Oslo, Norway



Elected Member
Christof von Kalle
Heidelberg, Germany



OECI Central Office
Guy Storme
Brussels, Belgium

WORKING
GROUPS AND
ACTIVITIES



Accreditation and Designation
Simon Oberst
Cambridge, United Kingdom



Biobanks and Molecular Pathobiology
Giorgio Stanta
Trieste, Italy



Cancer Economics and Benchmarking
Wim H. van Harten
Amsterdam, The Netherlands



Cancer Outcomes Research
Milena Sant
Milan, Italy



Supportive and Palliative Care
Tiina Hannele Saarto
Helsinki, Finland



Collaboration for Good Practices with Patients
Dominique de Valeriola
Brussels, Belgium



START-OECI
Lisa Licitra
Milan, Italy



Communication and Dissemination
Gordon McVie
Milan, Italy



Claudio Lombardo
Brussels, Belgium
Genoa, Italy

OECI-EEIG Central Office
c/o Fondation Universitaire
11, Rue d'Egmont
B-1000 Brussels, Belgium
Phone: +32 2 512 0146

www.oeci.eu
oeci@oeci.eu

October 2017



Organisation
of European
Cancer Institutes

*e*cancermedicalscience

Official OECI Journal

DEVELOPING
THE FUTURE IN
COMPREHENSIVE
CANCER CARE

ONE MORE REASON
TO JOIN THE OECI,
IS CERTIFYING
YOUR EXCELLENCE
IN ONCOLOGY!



OECI Objectives

The OECI is a network of cancer Institutions established to create a critical mass of expertise and competences and contributing to the production and dissemination of knowledge, so as to reduce fragmentation and increase competitiveness. These goals are being achieved by promoting and strengthening the concept of “comprehensiveness”, supporting quality in cancer care also through a well-structured internal organisation. OECI aims to accelerate the production and application of personalised care approaches, and to ensure equal rights to all cancer patients, with the ultimate goal of finding new and better treatments, providing more comprehensive care and improving patient quality of life, through evidence-based medicine.

The increasing interest from international organisations, stakeholders & the cancer community in the OECI points to the growing importance of a comprehensive cancer network of institutions, where the entire chain of cancer care provision is present.

Dominique de Valeriola
OECI President




“ The OECI is a non-governmental, non-profit Organisation founded in Vienna in 1979 and remodelled in 2005 into OECI-EEIG, a European Economic Interest Grouping, headquartered in Brussels. Today, the OECI counts 81 Member Institutes, which include some of the most prominent European Comprehensive Cancer Centres ”

OECI NETWORK 2017

The OECI membership 2017

Austria

- Comprehensive Cancer Center Graz, Graz
- Comprehensive Cancer Center Vienna, Wien
- Zentrum für Tumorerkrankungen Linz
Onkologisches Leitspital für Oberösterreich, Linz

Belgium

- ★ Institut Jules Bordet (IJB), Brussels
- ★ Kankercentrum Brussel, Brussels
- ★ AZ Groeninge, Kortrijk
- Institut Roi Albert II, Brussels

Croatia

- Klinika za tumore Klinicki bolnicki centar
Sestre milosrdnice, Zagreb

Czech Republic

- ★ Masarykův onkologický ústav, Brno
- Institut biostatistiky a analýz Lékařské a
Přirodovědecké fakulty Masarykovy university,
Brno

Denmark

- ★ Vejle Sygehus-Patienternes
Kræftsygehus, Vejle
- Kræftens Bekæmpelse Center
for Kræftforskning, Copenhagen

Estonia

- ★ Sihtasutus Tartu Ülikooli Kliinikum, Tartu
- North Estonia Medical Centre, Tallin

Finland

- ★ HYKS Syöpäkeskus Helsinki
University, Helsinki
- ★ Tampere University Hospital, Tampere
- ★ TYKS Syöpäkeskus, Turku

France

- ★ Gustave Roussy, Villejuif
- ★ Centre Léon Bérard, Lyon
- ★ Institut Curie, Paris
- Centre de Lutte Contre le Cancer
Paul Strauss, Strasbourg
- Centre Henri Becquerel, Rouen
- Centre Jean Perrin, Clermont-Ferrand
- Institut Paoli - Calmettes, Marseille

Germany

- Deutsches Krebsforschungszentrum (DKFZ),
Heidelberg
- Universitäts KrebsCentrum Dresden, Dresden
- Charité Comprehensive Cancer Centre, Berlin

Hungary

- ★ Országos Onkológiai Intézet, Budapest
- Országos Korányi TBC és Pulmonológiai
Intézet, Budapest

Ireland

- Trinity St. James's Cancer Institute, Dublin

Italy

- ★ Centro di Riferimento Oncologico,
Istituto Nazionale Tumori, Aviano
- ★ IRCCS Azienda Ospedaliera
Universitaria San Martino - IST -
Istituto Nazionale per la Ricerca
sul Cancro, Genova
- ★ Istituto Europeo di Oncologia, Milano
- ★ Fondazione IRCCS Istituto Nazionale
dei Tumori di Milano, Milano
- ★ Istituto Nazionale Tumori Regina Elena,
Roma
- ★ Istituto Oncologico Veneto IRCCS-IOV,
Padova
- ★ IRCCS Istituto Clinico Humanitas, Milano
- ★ Istituto Tumori Giovanni Paolo II,
Istituto di Ricovero e Cura a Carattere
Scientifico, Bari
- ★ Istituto Nazionale Tumori IRCCS
“Fondazione G.Pascale” (INT-Pascale),
Napoli
- ★ IRCCS, Centro di Riferimento Oncologico
della Basilicata (CROB), Rionero in Vulture
- ★ Azienda Ospedaliera Arcispedale
S. Maria Nuova IRCCS Istituto in
Tecnologie Avanzate e Modelli Assistenziali
in Oncologia, Reggio Emilia
- Ospedale S. Raffaele (OSR), Milano
- European School of Oncology (ESO), Milano
- IFOM - FIRC Institute of Molecular Oncology,
Milano
- Istituto Scientifico Romagnolo per lo
Studio e la Cura dei Tumori [IRST]-IRCCS,
Meldola - Forlì
- IRCCS - Istituto di Ricerche Farmacologiche
Mario Negri, Milano
- Ente Ospedaliero Ospedali Galliera, Genova
- Istituto Dermatologico S. Gallicano, Roma

Lithuania

- ★ National Cancer Institute, Vilnius

Norway

- ★ Oslo Universitetssykehus (OUS), Oslo

Poland

- Wielkopolskie Centrum Onkologii, Poznan

Portugal

- ★ Instituto Português de Oncologia
do Porto Francisco Gentil E.P.E.
(IPO-Porto), Porto

- ★ Instituto Português de Oncologia de
Lisboa Francisco Gentil, E.P.E.
(IPO-Lisboa), Lisbon

- ★ Instituto Português de Oncologia de
Coimbra Francisco Gentil, E.P.E.
(IPO-Coimbra), Coimbra

Romania

- ★ The “Prof. Dr. Ion Chiricută” Institute
of Oncology (IOCN), Cluj
- SC RTC Radiology Therapeutic Center –
Amethyst Radiotherapy, Otopeni

Russia

- Tatarstan Cancer Center “TCC”, Kazan
- N.N. Blokhin Russian Cancer Research
Centre, Moscow
- National Medical Research Radiological Centre
(NMRRC), Moscow

Serbia

- Oncology Institute of Vojvodina, Sremska Kamenica

Slovakia

- Biomedical Research Center SAS, Bratislava

Slovenia

- Onkološki inštitut Ljubljana, Ljubljana

Spain

- ★ Fundación Instituto Valenciano de
Oncología IVO, Valencia
- Institut Català d'Oncologia, L'Hospitalet
de Llobregat - Barcelona

Sweden

- Karolinska Institute and University,
Hospital, Stockholm

The OECI Quality Network

- ★ OECI Members A&D certified
Comprehensive Cancer Centre
- ★ OECI Members A&D certified
Clinical Cancer Centre
- ★ OECI Members in the A&D process
- Other OECI Members

